Evaluation of sampling spacing in pharmacokinetic studies using six sigma method

Area of Science:

• Pharmacokinetics
• Biostatistics
• Drug Development

Background:

• Pharmacokinetic (PK) studies are crucial for drug development, with sampling point number and spacing being key elements.
• Regulatory agency (RA) guidelines offer general rules for distributing sampling points but lack specific optimization methods.
• Assessing the quality of sampling point spacing (SSP) is essential for reliable PK parameter estimation.

Purpose of the Study:

• To demonstrate the effectiveness of the Six Sigma (SX) method for assessing the quality of sampling point spacing (SSP) in PK studies.
• To provide a quantitative method for comparing the quality of PK studies conducted at different centers.
• To align PK study quality assessment with RA recommendations.

Main Methods:

• A modified Six Sigma (SX) method was developed and applied to analyze PK data.
• Data from 466 PK profiles across 16 studies involving 368 healthy volunteers were analyzed.
• Non-compartmental modeling was employed to estimate PK parameters and calculate SX values.

Main Results:

• The arithmetic means of minimum and maximum SX values per subject were 1.97 and 3.83, respectively.
• The SX method demonstrated effectiveness in assessing SSP quality across diverse PK profiles.
• The method allows for objective comparison of PK study quality irrespective of chemical entity or study center.

Conclusions:

• The Six Sigma (SX) method provides a robust and quantitative approach to assess the quality of sampling point spacing in PK studies.
• SX values can serve as a reliable metric for evaluating PK study quality, supporting regulatory compliance.
• This method facilitates standardized quality assessment across different research settings and drug compounds.